ClinicalTrials.gg
CompletedNCT04864652ARCTIC-1Updated Jun 26, 2025

Safety and Dosing Study of the CHILLS Cryotherapy for the Treatment of OSA

An interventional study of CHILLS Procedure in Obstructive Sleep Apnea of Adult, sponsored by Cryosa, Inc.. Completed at 2 sites in 2 countries. Open to participants aged 22 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-06-26.

Sponsored by Cryosa, Inc. · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Aug 2022, 4 years 2 months ago, and no results have been posted to the registry.
  • Registered 3 months after the study started (first participant enrolled Nov 2020, registered Mar 2021).
Phase
Not applicable
Study type
Interventional
Enrollment
84
Allocation
Not applicable
Ages
22 Years to 65 Years
Sex
All
01

Study summary

ARCTIC-1 is a safety and dosing study to evaluate procedure tolerability in patients with clinically diagnosed moderate or severe OSA.

Read the detailed description

The study is a safety and dose titration study to determine the optimum dose of Cryosa CHILLS cryotherapy in patients with clinically diagnosed moderate or severe OSA.

Up to 70 subjects are planned to be enrolled and treated with the device at up to 3 clinical sites in Latin America. Subjects will be followed for 90 days with evaluation intervals at discharge, 7 days, 30 days and 90 days post-procedure. Subjects agreeing to long-term follow-up will complete visits every 6 months through 2 years post-procedure.

02

Conditions studied

  • Obstructive Sleep Apnea of Adult
03

In context

Sleep Apnea, Obstructive

2,240 studies on the registry are indexed under Sleep Apnea, Obstructive; 475 are open to participants now.

This study's enrollment of 84 is above the median of 52 across 1,472 interventional studies indexed under Sleep Apnea, Obstructive.

Browse Sleep Apnea, Obstructive studies →

Lead sponsor

Cryosa, Inc. is the lead sponsor of 5 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
22 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 25 - 65 years.
  2. Diagnosed with moderate to severe OSA based on history and physical or have an established diagnosis of OSA (AHI ≥ 15 and ≤ 50) based on a prior sleep study.
  3. is between 28 kg/m2 and 40 kg/m2 at enrollment.
  4. Negative result for COVID-19 polymerase chain reaction (RT-PCR) test and absence of clinical symptoms for COVID-19.

Exclusion criteria

Exclusion Criteria:

  1. Subjects with a high percentage of central apneas suggesting heart failure.
  2. to general anesthesia and MRI.
  3. Metal braces, plate or pieces in the head or jaw that may interfere with MRI.
  4. Craniofacial abnormality (e.g. retrognathia, micrognathia, etc.) thought to be the primary cause of OSA.
  5. Obvious fixed upper airway obstructions (tumors, polyps, nasal obstruction) .
  6. Tonsil size ≥ +3.
  7. Previous surgery within 12 weeks of scheduled procedure performed on the soft tissue of the upper airway (e.g., uvula, soft palate or tonsils).
  8. Oral cancer or non-healing oral wounds.
  9. Presence of symptoms of influenza-like symptoms.
  10. Contra-indicated for anesthesia or surgery.
  11. History of surgery affecting the tongue (TORS, semi-glossectomy, RFBOT, MMA, HGNS).
  12. History of radiation therapy to neck or upper respiratory tract
  13. Surgical resection for cancer or congenital malformations in the larynx, tongue, or throat (with exception of tonsillectomy and/or adenoidectomy).
  14. Clinical evidence of severe chronic obstructive or restrictive pulmonary disease (for example chronic bronchitis, emphysema, pulmonary fibrosis).
  15. Active, severe pulmonary vascular disease (for example pulmonary arterial hypertension or pulmonary embolism).
  16. Currently receiving treatment for severe cardiac valvular dysfunction, Class III or IV heart failure, unstable angina or recent (\< 12 month) myocardial infarction or severe cardiac arrhythmias.
  17. Subjects with bleeding event, known bleeding diathesis, impaired immunity for any reason, or heart attack or stroke within the last 12 months.
  18. Clinical evidence of severe renal failure (Stage 4 or 5) undergoing dialysis or expected to institute dialysis within 12 months.
  19. History or current clinical evidence of or stroke or muscular dysfunction.
  20. Taking medications that in the opinion of the consulting physician may alter consciousness, the pattern of respiration, or sleep architecture, such examples being benzodiazepines, opiates, neuroleptics, prescription stimulants, phenothiazine, or any form of chemical substance abuse.
  21. History of dementia or active psychiatric disease that may impact study compliance.
  22. Females who are pregnant or females of childbearing age with intention to become pregnant during the study period (≤ 3 months from treatment date).
  23. Unable and/or unwilling to comply with study requirements or to provide written .
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
84 participants (actual)

Study arms

  • Experimental
    Single Arm

    CHILLS Procedure

    Device: CHILLS Procedure

Interventions

  • DeviceCHILLS Procedure

    CHILLS Cryotherapy procedure

06

What researchers measure

Primary outcomes

  1. Incidence of Serious Procedure-Related Complications

    No serious procedure-related complications including death, loss of the airway requiring post-anesthesia care unit (PACU) re-intubation, persistent loss (more than 30 days) of tongue movement, or bleeding requiring surgical intervention or transfusion.

    Time frame: 30 Days

07

Study locations

2 sites
  • Paitilla Medical Center
    Panama City, Panama
  • Sanatorio Americano
    Asunción, Paraguay
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04864652
Lead sponsor
Cryosa, Inc.
Responsible party
Sponsor
First posted
Apr 29, 2021
Start date
Nov 30, 2020
Primary completion
Aug 25, 2022
Completion
May 6, 2023
Last update
Jun 26, 2025

Study contacts

Marquito Caballero, MD
principal investigator · Sanatorio Americano
Stella Rowley, MD
principal investigator · San Fernando Specialized Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion